Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hepatic encephalopathy primary prevention
Introduction
Overview
Overview
Usage of lactulose is helpful in prevention of HE in patients with cirrhosis and acute variceal bleeding. Lactulose may be effective to prevent of recurrence of hepatic encephalopathy in patients with cirrhosis.
Primary Prevention
Primary Prevention
- Usage of lactulose is helpful in prevention of hepatic encephalopathy in patients with cirrhosis and acute upper gastrointestinal bleeding.[1][2]
- Lactulose may be effective to prevent of recurrence of hepatic encephalopathy in patients with cirrhosis.[3]
- Usage of lactitol or rifaximin is not effective in the prophylaxis of hepatic encephalopathy during the first month after a transjugular-intrahepatic-portosystemic-shunt (TIPS).[4]
References
References
- ↑ Aires FT, Ramos PT, Bernardo WM (2016). “Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding”. Rev Assoc Med Bras (1992). 62 (3): 243–7. doi:10.1590/1806-9282.62.03.243. PMID 27310548.
- ↑ Sharma P, Agrawal A, Sharma BC, Sarin SK (2011). “Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose”. J Gastroenterol Hepatol. 26 (6): 996–1003. doi:10.1111/j.1440-1746.2010.06596.x. PMID 21129028.
- ↑ Sharma BC, Sharma P, Agrawal A, Sarin SK (2009). “Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo”. Gastroenterology. 137 (3): 885–91, 891.e1. doi:10.1053/j.gastro.2009.05.056. PMID 19501587.
- ↑ Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM; et al. (2005). “Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study”. J Hepatol. 42 (5): 674–9. doi:10.1016/j.jhep.2004.12.028. PMID 15826716.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]